KG&L Capital Management LLC Lowers Position in GSK PLC Sponsored ADR (NYSE:GSK)

KG&L Capital Management LLC trimmed its position in GSK PLC Sponsored ADR (NYSE:GSK) by 2.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,655 shares of the pharmaceutical company’s stock after selling 376 shares during the period. KG&L Capital Management LLC’s holdings in GSK were worth $488,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Sequoia Financial Advisors LLC lifted its position in GSK by 12.8% during the 1st quarter. Sequoia Financial Advisors LLC now owns 23,294 shares of the pharmaceutical company’s stock valued at $902,000 after acquiring an additional 2,649 shares during the period. Golden State Wealth Management LLC grew its stake in shares of GSK by 100.3% in the 1st quarter. Golden State Wealth Management LLC now owns 2,277 shares of the pharmaceutical company’s stock worth $88,000 after buying an additional 1,140 shares during the last quarter. First Pacific Financial bought a new position in GSK during the 1st quarter valued at approximately $45,000. Aurora Private Wealth Inc. bought a new stake in GSK in the first quarter worth $692,000. Finally, Ledyard National Bank grew its stake in shares of GSK by 15.5% in the first quarter. Ledyard National Bank now owns 44,504 shares of the pharmaceutical company’s stock worth $1,724,000 after acquiring an additional 5,960 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Price Performance

Shares of GSK stock opened at $38.27 on Thursday. The stock has a market cap of $78.35 billion, a P/E ratio of 19.73, a P/E/G ratio of 1.35 and a beta of 0.52. The company has a debt-to-equity ratio of 1.21, a quick ratio of 0.58 and a current ratio of 0.87. The stock’s fifty day moving average is $38.75 and its 200 day moving average is $36.89. GSK PLC Sponsored ADR has a one year low of $31.72 and a one year high of $44.67.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, topping the consensus estimate of $1.08 by $0.05. The firm had revenue of $10.06 billion for the quarter, compared to the consensus estimate of $7.52 billion. GSK had a return on equity of 48.82% and a net margin of 9.89%. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.43 earnings per share. Sell-side analysts anticipate that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be given a dividend of $0.4216 per share. This represents a $1.69 annualized dividend and a dividend yield of 4.41%. This is an increase from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, May 16th. GSK’s dividend payout ratio (DPR) is presently 87.11%.

Wall Street Analyst Weigh In

GSK has been the topic of a number of recent analyst reports. Wall Street Zen cut shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, May 30th. Hsbc Global Res raised GSK to a “strong sell” rating in a report on Monday, April 28th. BNP Paribas assumed coverage on GSK in a report on Tuesday, April 15th. They set a “neutral” rating and a $35.25 price target on the stock. Finally, Berenberg Bank reiterated a “hold” rating on shares of GSK in a report on Tuesday, June 3rd. One analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.